PharmaTelevision - REGiMMUNE: Molecules and programs

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: REGiMMUNE: Molecules and programs

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Haru Morita, CEO & President, about the origins and technology of REGiMMUNE. They discuss:

• Mechanism of reverse vaccination

• Molecules and programs in preclinical stage and specific targets

• Funding and partnership strategies

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Origins and technology of REGiMMUNE

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at the Japan Biotech Forum at The Royal Society in London. On this show I have Haru Morita, who is the CEO and President of a company called REGiMMUNE which is based in Tokyo, welcome to the show.

Haru Morita:

Thank you very much.

Fintan Walton:

REGiMMUNE, is a biotech company an emerging company within Japan, your company is very specialized in the area of reverse vaccination as I understand it, could you tell me a little bit about the origin of the company and the technology that's associated with that company?

Haru Morita:

Okay, the company was established in 2006 along the IP developed at RIKEN. RIKEN is Japanese leading research institute, and the technology developed at RIKEN is their target specific immunosuppressant technology and we name it as reVax.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Haru Morita

President

Haru Morita , has served as President, Chief Executive Officer and Director of REGiMMUNE since March 2006. Prior to REGiMMUNE, Mr. Haru Morita served on the management teams of Y's Therapeutics, Ltd. and Y's Therapeutics, Ltd., most recently as Director of Business Development with responsibility for corporate planning as well. Mr. Haru Morita 's professional experience also includes management consulting at Booz Allen and Hamilton (Tokyo office). In this capacity as consultant, he helped clients to establish and implement strategy not only in pharmaceutical business but also in other area such as chemical and consumer products. Prior to that, Mr. Haru Morita worked as a research scientist in the medical research division of Kirin Brewery Co. Ltd (lately it merged into Kyowa-Hakko-Kirin). At Kirin he was a part of the research and development team that was first to clone Megakaryocyte Growth and Differentiation Factor (MDGF or Thrombopoietin). He received both a BS in Chemical Engineering and an MS in Molecular and Cellular Biology from the University of Tokyo.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

REGiMMUNE

The REGiMMUNE is a biotechnology company focused on the discovery, development, and potential commercialization of immune-regulatory therapeutics to treat life-threatening diseases and debilitating disorders, including allergies, autoimmune and inflammatory disease. REGiMMUNE applies its reVax (reverse vaccination) technology and product development and clinical experience to generate, support and potentially commercialize a broad range of products for itself and its partners. REGiMMUNE's business strategy is to develop novel and proprietary products focused on therapeutics areas that can be addressed with immune-regulating technology and expedite programs by actively using outside resources and partnering with biotechnology and pharmaceutical companies to leverage technology assets. REGiMMUNE Corporation 's growth is driven by our flexible and precision management based on clear-sighted vision.